SHANGHAI - XW Laboratories Inc.'s lead candidate, a small-molecule drug for narcolepsy, has begun dosing in healthy patients in Australia. Based in Wuhan and Taipei, XW Labs decided to head to Australia for phase I for a variety of reasons, even though moving to first-in-human trials in China has become more viable after CFDA reforms.